For Cancer Survivors, This Type of Test May Be Key

Wall Street's newest cancer bet isn't about finding tumors early, but about making sure they're really gone. The Wall Street Journal reports on Natera, a company based in Austin, Texas, that has quietly come to dominate "minimal residual disease" (MRD) testing, a blood-based way to spot cancer's return months before scans typically can. Its flagship test, Signatera, is customized to each patient: Doctors send in the removed tumor, then Natera maps its unique DNA and builds a blood test that hunts for those exact mutations during follow-up visits. The test is key, because "by the time a tumor shows up on imaging, it's often too late," one oncologist tells the Journal.

The firm's financial story is as aggressive as its science. Natera's revenue has more than doubled over the past couple of years, and its value has surged to roughly $31 billion, outpacing even sequencing heavyweight Illumina. StockStory notes, however, that the company had mixed first-quarter results this year, and because expectations are sky-high, any hint of slower growth rattles investors. The Journal explores how clinical trial evidence, insurance coverage, competition from biotech firms like Guardant Health, and even basic awareness among community doctors and patients will determine whether the type of MRD testing offered by Natera eventually becomes routine cancer care. More here.